title: Characterization of peripheral blood progenitor cells (PBPC) mobilized by filgrastim (rHuG-CSF) in normal volunteers: dose-effect relationship for filgrastim with the character of mobilized PBPC.
abstract: Filgrastim (rHuG-CSF)-mobilized peripheral blood progenitor cells (PBPC) in healthy Japanese volunteers were characterized in detail using two clonal cell culture systems and double-colour flow cytometry to detect multilineage colony-forming cells and subsets of CD34+ cells. The kinetics of PBPC during the administration of filgrastim was studied, and possible differences in the character of progenitor cells relative to given doses of filgrastim were investigated. Filgrastim was administered subcutaneously to normal volunteers for 7 d at doses of 100, 200 or 400 microgram/m2 (10 per cohort). Treatment with 100 or 200 microgram/m2 filgrastim was well tolerated; however, the 400 microgram/m2 dose level was not completed because of bone pain and myalgia. The treatment strikingly mobilized various types of progenitor cells, including highly proliferative megakaryocytic colony-forming cells. The number of progenitor cells peaked on days 5 and 6. The fold increase of circulating progenitor cells from the baseline value in the volunteers treated with 200 microgram/m2 filgrastim was more pronounced than in those treated with 100 microgram/m2. Treatment with 200 microgram/m2 also released the less mature progenitor cells (i.e. mixed colony-forming cells CD34+/33- cells, and CD34+/HLA-DR-cells) into circulation better than the 100 microgram/m2 dose. These results suggest that daily subcutaneous injection with 200 microgram/m/2 filgrastim for 5 d will effectively mobilize, both qualitatively and quantitatively, PBPC in healthy donors.
authors.affiliation: Department of Clinical Oncology / Paediatrics and Blood Transfusion, Institute of Medical Science, University of Tokyo, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Tanaka
authors.forename: T
authors.initials: T
authors.lastname: Matsudaira
authors.forename: J
authors.initials: J
authors.lastname: Aizawa
authors.forename: Y
authors.initials: Y
authors.lastname: Ebihara
authors.forename: K
authors.initials: K
authors.lastname: Muraoka
authors.forename: K
authors.initials: K
authors.lastname: Tsuji
authors.forename: K
authors.initials: K
authors.lastname: Ikebuchi
authors.forename: K
authors.initials: K
authors.lastname: Kodama
authors.forename: F
authors.initials: F
authors.lastname: Takaku
authors.forename: T
authors.initials: T
authors.lastname: Nakahata
mesh_terms: D000328:Adult; D018952:Antigens, CD34 / Q000378:metabolism; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D000069585:Filgrastim; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology*; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000494:pharmacology
chemical_list: D018952:Antigens, CD34; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim